Seeking Alpha
 

Regeneron Pharmaceuticals, Inc. (REGN)

- NASDAQ
  • Tue, Aug. 4, 8:43 AM
    • Regeneron Pharmaceuticals (REGN +0.1%) Q2 results: Revenues: $998.6M (+50.0%); COGS: $60.9M (+103.7%); R&D Expense: $390.3M (+32.5%); SG&A: $174.6M (+80.6%); Operating Income: $344.9M (+51.2%); Net Income: $194.6M (+101.9%); EPS: $1.69 (+98.8%); Quick Assets: $1,193.8M (-12.3%).
    • Eylea U.S. sales: 655 (+57.8%).
    • 2015 Guidance: Eylea U.S. net product sales growth: 45 - 50% from 30 - 35%; non-GAAP unreimbursed R&D: $510M - 550M from $525M - 575M; non-GAAP SG&A: $610M - 650M from $650M - 725M; CAPEX: $675M - 750M from $650M - 750M.
    | Tue, Aug. 4, 8:43 AM | 1 Comment
  • Tue, Aug. 4, 6:31 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN): Q2 EPS of $2.89 beats by $0.12.
    • Revenue of $998.62M (+50.0% Y/Y) beats by $110.81M.
    • Shares +1.21% PM.
    • Press Release
    | Tue, Aug. 4, 6:31 AM | 5 Comments
  • Mon, Aug. 3, 11:28 AM
    • Regeneron Pharmaceuticals (REGN -0.3%) will report Q2 results tomorrow before the open. Consensus view is EPS of $2.77 (+12%) on revenues of $888M (+33%).
    | Mon, Aug. 3, 11:28 AM | 1 Comment
  • Thu, May 7, 8:04 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN) Q1 results ($M): Revenues: 869.6 (+39.0%); Net Product Sales: 544.6 (+50.3%); Sanofi Collaboration Revenue: 173.4 (+28.4%); Bayer Healthcare Collaboration Revenue: 123.8 (-1.2%); Technology Licensing/Other: 27.8 (+270.7%); Operating Income: 283.6 (+48.0%); Net Income: 76.0 (+11.3%); EPS: 0.66 (+8.2%); Quick Assets: 1,225.5 (-10.0%).
    • Eylea U.S. sales: 541 (+50.7%); ex-U.S. sales: 292 (+33.9%).
    • 2015 Guidance: Eylea U.S. net product sales growth: 30 - 35% from 25 - 30%.
    | Thu, May 7, 8:04 AM | 1 Comment
  • Thu, May 7, 6:31 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN): Q1 EPS of $2.88 beats by $0.20.
    • Revenue of $870M (+39.0% Y/Y) beats by $45.36M.
    • Press Release
    | Thu, May 7, 6:31 AM | 3 Comments
  • Tue, Feb. 10, 9:47 AM
    • Regeneron Pharmaceuticals (REGN -0.1%) Q4 results ($M): Total Revenues: 802.3 (+31.4%); Net Product Sales: 521.5 (+28.4%); Sanofi Collaboration Revenue: 135.3 (+21.9%); Bayer Collaboration Revenue: 137.1 (+60.0%); Eylea Sales: 518.0 (+28.9%); Operating Income: 247.4 (+16.6%); Net Income: 110.2 (+13.8%); EPS: 0.96 (+11.6%).
    • 2015 Guidance: Net Product Sales: 25 - 30% growth; Non-GAAP R&D: $525M - 575M; Non-GAAP SG&A: $650M - 725M; CAPEX: $650M - 800M.
    | Tue, Feb. 10, 9:47 AM | 2 Comments
  • Tue, Feb. 10, 6:32 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN): Q4 EPS of $2.79 misses by $0.02.
    • Revenue of $802.32M (+31.4% Y/Y) beats by $20.8M.
    • Press Release
    | Tue, Feb. 10, 6:32 AM | Comment!
  • Mon, Feb. 9, 5:30 PM
  • Fri, Jan. 9, 10:00 AM
    • Regeneron Pharmaceuticals (REGN +1.4%) will report Q4 and full-year results on February 10 before the open. The conference call will begin at 8:30 am ET.
    • Consensus revenue views for Q4 and 2014 are $775M and $2.8B, respectively.
    | Fri, Jan. 9, 10:00 AM | Comment!
  • Nov. 6, 2014, 11:09 AM
    • Regeneron (REGN +1.1%) Q3 results: Revenues: $725.8M (+21.6%); Eylea Sales: $448.8M (+22.3%); R&D Expense: $337.7M (+50.8%); SG&A: $149.7M (+53.4%); Operating Income: $182.7M (-22.8%); Net Income: $79.7M (-43.6%); EPS: $0.70 (-44.0%); Quick Assets: $1,495.6M (+38.0%).
    • 2014 Guidance: Eylea sales: $1.7B - 1.74B from $1.7B - 1.8B; R&D: $490M - 510M from $470M - 510M; SG&A: $330M - 350M from $310M - 350M; CAPEX: $300M - 350M from $350M - 425M.
    • Follow up from initial post on November 4.
    | Nov. 6, 2014, 11:09 AM | 1 Comment
  • Nov. 4, 2014, 6:31 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN): Q3 EPS of $2.52 misses by $0.05.
    • Revenue of $726M (+21.6% Y/Y) misses by $7.04M.
    • Press Release
    | Nov. 4, 2014, 6:31 AM | 1 Comment
  • Oct. 15, 2014, 4:30 PM
    • Regeneron Pharmaceuticals (REGN +2%) will report Q3 results on November 4 before the open. The conference call will begin at 8:30 am ET.
    • Consensus view is EPS of $2.57 on revenues of $732M.
    | Oct. 15, 2014, 4:30 PM | Comment!
  • Aug. 5, 2014, 6:56 AM
    • Regeneron (NASDAQ:REGN) Q2 results: Total Revenues: $665.7M (+45.5%), Eylea Sales: $415M (+24.3%); Operating Expenses: $443.3M (+48.0%); Operating Income: $222.4M (+40.7%); Net Income: $92.7M (+6.1%); EPS: $0.82 (+3.8%); Quick Assets: $1,367.7M (+26.2%).
    • 2014 Guidance: Eylea sales: $1.7B - 1.8M; R&D: $470M - 510M from $425M - 475M; SG&A: $310M - 350M from $330M - 380M; CAPEX: $350M - 425M.
    | Aug. 5, 2014, 6:56 AM | 1 Comment
  • Aug. 5, 2014, 6:31 AM
    • Regeneron Pharmaceuticals (NASDAQ:REGN): Q2 EPS of $2.47 beats by $0.18.
    • Revenue of $666M (+45.5% Y/Y) beats by $18.01M.
    • Press Release
    | Aug. 5, 2014, 6:31 AM | Comment!
  • May 8, 2014, 7:24 AM
    • Regeneron Pharmaceuticals (REGN) total revenues: $626M (+42.3%); collaboration revenues: $256M (+124.6%); net product sales: $362M (+13.5%); Eylea sales: $359M (+14.3%); Arcalyst sales: $3M (-40%); operating income: $186M (+21.5%); net income: $65.4M (-33.9%); EPS: $0.58 (-35.6%); quick assets (ex-A/R): $1.2B (+9.1%).
    • Eylea PDUFA date for macular edema indication is August 18, 2014.
    • Eylea PDUFA date for macular edema following branch retinal vein occlusion indication is October 23, 2014.
    • Fifteen human monoclonal antibodies generated by the company's VelocImmune technology are in clinical development, including eight with Sanofi (SNY).
    | May 8, 2014, 7:24 AM | 1 Comment
  • May 8, 2014, 6:31 AM
    • Regeneron Pharmaceuticals (REGN): Q1 EPS of $2.26 in-line.
    • Revenue of $626M (+42.4% Y/Y) beats by $16.96M.
    • Press Release
    | May 8, 2014, 6:31 AM | Comment!
Visit Seeking Alpha's
REGN vs. ETF Alternatives
Company Description
Regeneron Pharmaceuticals Inc is a fully integrated biopharmaceutical company. It discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
Sector: Healthcare
Industry: Biotechnology
Country: United States